Kailera Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KLRA research report →
Range $36 – $48
Price Chart
About the company
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules.
- CEO
- Ronald C. Renaud Jr.
- IPO
- 2026
- Employees
- 145
- HQ
- Waltham, MA, US
Get TickerSpark's AI analysis on KLRA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.43B
- P/E
- -3.82
- PEG
- 0.04
- P/S
- 0.00
- P/B
- 1.46
- EV/EBITDA
- -3.81
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -102.35%
- ROIC
- -36.45%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-158,340,000
- Net Income
- $-148,955,000+0.0%
- EPS
- $-1.26+0.0%
- OCF Growth
- +0.0%
- FCF Growth
- +0.0%
- 52W High
- $28.23
- 52W Low
- $9.76
- 50D MA
- $12.28
- 200D MA
- $17.50
- Beta
- 0.50
- RSI (14)
- 41
- Avg Volume
- 1.08M
No earnings-call transcripts are available for KLRA yet.
- Free Float
- 68.9%
- Shares Outstanding
- 129.85M
- Float Shares
- 89.53M
of shares held by institutions
102 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Bain Capital Investors LLC | 26.26M | ▲ 26.26M |
| Bain Capital Life Sciences Investors, LLC | 22.58M | ▲ 22.58M |
| Rtw Investments, LP | 10.78M | ▲ 10.78M |
| Canada Pension Plan Investment Board | 7.30M | ▲ 7.30M |
| Atlas Venture Life Science Advisors, LLC | 5.17M | 0 |
| Fmr LLC | 4.66M | ▲ 689.02K |
| Blackrock, Inc. | 4.57M | ▲ 644.41K |
| Price T Rowe Associates Inc | 3.53M | ▲ 3.53M |
| Citadel Advisors LLC | 3.24M | ▲ 3.24M |
| Adage Capital Partners Gp, L.L.C. | 3.21M | ▲ 3.21M |
| Wellington Management Group Llp | 2.92M | ▲ 2.92M |
| Royalty Pharma Sub-Manager, LLC | 2.46M | 0 |
Held by 198 ETFs
Biggest fund positions in KLRA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 7, 26 | Nicholson Nur | other | 220,000 |
| Aug 31, 26 | Nicholson Nur | other | 0 |
| Jul 6, 26 | Tregoning Kathleen | other | 175,000 |
| Jun 29, 26 | Tregoning Kathleen | other | 0 |
| Jun 9, 26 | Renaud Ronald C JR | other | 38,094 |
| Jun 9, 26 | Renaud Ronald C JR | other | 38,094 |
| Apr 20, 26 | RTW INVESTMENTS, LP | buy | 500,000 |
| Apr 20, 26 | RTW INVESTMENTS, LP | other | 10,276,820 |
| Apr 20, 26 | RTW INVESTMENTS, LP | other | 8,250,000 |
| Apr 20, 26 | RTW INVESTMENTS, LP | other | 2,026,820 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our KLRA coverage
Recent articles, reports, and earnings notes.
No research on KLRA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate KLRA report →Kailera Therapeutics to Present at ObesityWeek 2026
globenewswire.com · Nov 10
Kailera Reports Third Quarter 2026 Financial Results and Provides Business Updates
globenewswire.com · Nov 4
Kailera Therapeutics to Participate in November Investor Conferences
globenewswire.com · Nov 3
Kailera Therapeutics (NASDAQ:KLRA) Shares Climb 7.6% – Here’s What Happened
defenseworld.net · Oct 11
Kailera Therapeutics (NASDAQ:KLRA) Sets New 12-Month Low – Time to Sell?
defenseworld.net · Oct 5
Kailera Therapeutics Presents New Clinical Data at EASD 2026 Annual Meeting
globenewswire.com · Oct 1
Novo Is Open to Acquisitions. Here Are 2 Companies That Would Be Great Candidates to Buy
fool.com · Sep 30
Kailera Therapeutics Announces Completion of Enrollment in KaiNETIC Global Phase 3 Clinical Program of GLP-1/GIP Receptor Dual Agonist Ribupatide Injection
globenewswire.com · Sep 30
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.